<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="680">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152303</url>
  </required_header>
  <id_info>
    <org_study_id>HR7056-205</org_study_id>
    <nct_id>NCT05152303</nct_id>
  </id_info>
  <brief_title>A Study of Remimazolam Tosilate for Sedation in the ICU</brief_title>
  <official_title>Efficacy and Safety of Remimazolam Tosilate for Injection for Sedation in the Intensive Care Unit (ICU) - a Multicenter, Randomized, Single Blind, Positive Drug Parallel Controlled Phase II/â…¢ Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Shengdi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Shengdi Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longzhu Building, No.5 Zhusigang 2nd Road, Guangzhou city, Guangdong Province, China&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Remimazolam Tosilate compared with Propofol Injection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time maintaining target sedation in the entire drug administering time.</measure>
    <time_frame>within 24 hours after administration of research drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with the time maintaining target sedation accounting for a certain proportion in the entire drug administering time.</measure>
    <time_frame>within 24 hours after administration of research drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time maintaining sedation to some extent in the entire drug administering time.</measure>
    <time_frame>within 24 hours after administration of research drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reach the target sedation level at each preset assessment time point after drug administering.</measure>
    <time_frame>within 24 hours after administration of research drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake-up time.</measure>
    <time_frame>within 24 hours after stopping the research drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects suffering sedation failure.</measure>
    <time_frame>within 24 hours after administration of research drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of nursing difficulty.</measure>
    <time_frame>follow-up period (approx. 5-10 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time.</measure>
    <time_frame>at the time of extubation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">243</enrollment>
  <condition>Sedation in the ICU</condition>
  <arm_group>
    <arm_group_label>Remimazolam Tosilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosilate</intervention_name>
    <description>IV of Remimazolam Tosilate</description>
    <arm_group_label>Remimazolam Tosilate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Injection</intervention_name>
    <description>IV of Propofol Injection</description>
    <arm_group_label>Propofol Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients or their guardians are able to provide a written informed consent&#xD;
&#xD;
          2. Subjects have been treated with endotracheal intubation and mechanical ventilation,&#xD;
             and is expected to receive sedation after randomization. The target level and duration&#xD;
             of sedation meet the criteria&#xD;
&#xD;
          3. Meet the age criteria, male or female&#xD;
&#xD;
          4. Meet the BMI criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Deep sedation is required, or continuous sedation is not needed during the study&#xD;
             process&#xD;
&#xD;
          2. Subjects with a history of severe cardiovascular disease, or cerebrovascular disease,&#xD;
             or neurological disease, or mental illness&#xD;
&#xD;
          3. Subjects with a history of drug abuse&#xD;
&#xD;
          4. Subjects after neurosurgery operation&#xD;
&#xD;
          5. Organ failure before randomization&#xD;
&#xD;
          6. Abnormal values of the laboratory examination&#xD;
&#xD;
          7. Abnormal blood pressure and heart rate during screening&#xD;
&#xD;
          8. Allergic to relevant drugs ingredient or component&#xD;
&#xD;
          9. Pregnant or nursing women&#xD;
&#xD;
         10. Subjects who has participated in clinical trials of other interventions recently&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qin Liu, M.M</last_name>
    <phone>+0518-82342973</phone>
    <email>qin.liu@hengrui.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

